• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Oral Anticoagulation and the Incidence of Stroke Associated with Atrial Fibrillation in Mainland Portugal: A Modelling Study
CONCLUSION: The use of oral anticoagulation was associated with a reduced incidence of stroke in patients with atrial fibrillation in mainland Portugal. This reduction was more relevant in the period between 2016 and 2018, and is probably related with the introduction of the novel oral anticoagulants.PMID:37429703 | DOI:10.20344/amp.19255
Source: Acta Medica Portuguesa - July 10, 2023 Category: General Medicine Authors: Raquel Ascen ção Madalena Gil Francisco Louren ço Daniel Caldeira Ros ário Oliveira Margarida Borges Lu ís Silva Miguel Jo ão Costa Source Type: research

Founder effect of Fabry disease due to p.F113L mutation: Clinical profile of a late-onset phenotype
ConclusionA founder effect of FD due to p.F113L mutation was documented by genealogy and genetics in a Portuguese region. In this late-onset phenotype, although cardiac manifestations carry the highest prognostic impact, extracardiac involvement is common.
Source: Molecular Genetics and Metabolism - July 25, 2019 Category: Genetics & Stem Cells Source Type: research

Short- and medium-term prognosis of Takotsubo syndrome in a Portuguese population
ConclusionTTS has a good short- and medium-term prognosis. However, the rate of in-hospital complications is high and should not be overlooked. Dyspnea at presentation, CKD, CAD and lower LVEF on admission were independent predictors of in-hospital complications. Prolonged QTc on admission was associated with complications in follow-up.ResumoIntroduçãoA síndrome de Takotsubo (TTS) caracteriza-se por disfunção sistólica ventricular esquerda transitória.ObjetivoCaracterizar uma população portuguesa com TTS e determinar o seu prognóstico a curto e médio prazo.MétodosEstudo multicêntrico português com inclusão r...
Source: Revista Portuguesa de Cardiologia - July 6, 2019 Category: Cardiology Source Type: research

Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study
This study details the design of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study – a postauthorization observational study, which is part of the postapproval plan for edoxaban agreed with the European Medicines Agency. Methods The ETNA-AF-Europe study (Clinicaltrials.gov: NCT02944019) is a multicenter, prospective, observational study that enrolled 13 980 patients with atrial fibrillation treated with edoxaban from 852 sites across 10 European countries (Austria, Belgium, Germany, Ireland, Italy, the Netherlands, Portugal, Spain, Switzerland,...
Source: Journal of Cardiovascular Medicine - January 3, 2019 Category: Cardiology Tags: Research articles: Trial design Source Type: research

Health care cost analysis of enhanced pacing modalities in bradycardia patients: Portuguese case study on the results of the MINERVA trial
ConclusionThe combination of atrial preventive pacing, atrial antitachycardia pacing and an algorithm to minimize the detrimental effect of right ventricular pacing reduces recurrent and permanent AF. The new DDDRP + MVP pacing mode could contribute to significant costs savings in the Portuguese health care setting.ResumoIntroduçãoObservamos no estudo MINERVA que a prevenção de pacing auricular e antitaquicardia (DDDRP), em combinação com algoritmos de redução de pacing ventricular (MVP), reduzem a fibrilhação auricular (FA) permanente em doentes com bradicardia, com FA permanente ou paroxística que necessitam d...
Source: Revista Portuguesa de Cardiologia - December 28, 2018 Category: Cardiology Source Type: research

The SAFIRA study: A reflection on the prevalence and treatment patterns of atrial fibrillation and cardiovascular risk factors in 7500 elderly subjects
Conclusions This study shows the high prevalence of AF in the elderly population, as well as suboptimal rates of diagnosis, anticoagulation and effective control of cardiovascular risk factors.
Source: Revista Portuguesa de Cardiologia - April 24, 2018 Category: Cardiology Source Type: research

Portuguese Observational Study of Ischaemic Stroke in Patients Medicated with Non-Vitamin K Antagonist Oral Anticoagulants
Conclusion: Preadmission anticoagulation with NOACs in AIS has a functional impact similar to that of VKAs.Eur Neurol 2018;79:108 –112
Source: European Neurology - February 8, 2018 Category: Neurology Source Type: research

Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for atrial fibrillation in Portugal
Conclusions Apixaban is a cost-effective alternative to warfarin and dabigatran and is dominant over rivaroxaban in AF patients from the perspective of the Portuguese national healthcare system. These conclusions are based on indirect comparisons, but despite this limitation, the information is useful for healthcare decision-makers.
Source: Revista Portuguesa de Cardiologia - January 12, 2016 Category: Cardiology Source Type: research

Use of drug-eluting versus bare-metal stents after an acute coronary syndrome in Portugal: The EURHOBOP study
Conclusions Approximately two-thirds of patients received drug-eluting stents, which were less frequently implanted in patients with ST-elevation myocardial infarction, aged over 80 years, female, with a previous history of stroke, anticoagulation and/or atrial fibrillation and anemia. Patients who had previously undergone PCI and those with the anterior descending artery as the infarct-related artery were more likely to receive a drug-eluting stent.
Source: Revista Portuguesa de Cardiologia - August 5, 2015 Category: Cardiology Source Type: research

Burden of disease and cost of illness of atrial fibrillation in Portugal
Conclusions Atrial fibrillation has an important social impact in Portugal due to its associated mortality and morbidity, and was responsible in 2013 for a total cost of €140 million, about 0.08% of gross domestic product.
Source: Revista Portuguesa de Cardiologia - January 23, 2015 Category: Cardiology Source Type: research

Cost-effectiveness of rivaroxaban for stroke prevention in atrial fibrillation in the Portuguese setting
Conclusion The results showed that rivaroxaban may be a cost-effective alternative compared with warfarin or real-world prescribing in Portugal.
Source: Revista Portuguesa de Cardiologia - November 6, 2014 Category: Cardiology Source Type: research